摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-{3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl}-(S)-2-hydroxyethyl)-(S)-3H-isobenzofuran-1-one | 184764-52-1

中文名称
——
中文别名
——
英文名称
3-(2-{3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl}-(S)-2-hydroxyethyl)-(S)-3H-isobenzofuran-1-one
英文别名
(3R)-3-[(2S)-2-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-2-hydroxyethyl]-3H-2-benzofuran-1-one
3-(2-{3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl}-(S)-2-hydroxyethyl)-(S)-3H-isobenzofuran-1-one化学式
CAS
184764-52-1
化学式
C27H20ClNO3
mdl
——
分子量
441.914
InChiKey
BDRQGMUOCFFGGD-VUBCVZIDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    32
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    59.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(2-{3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl}-(S)-2-hydroxyethyl)-(S)-3H-isobenzofuran-1-one正丁基锂三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 17.25h, 生成 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-2-[(1R)-3-oxo-1H-2-benzofuran-1-yl]ethyl]sulfanylmethyl]cyclopropyl]acetic acid
    参考文献:
    名称:
    Synthesis of Montelukast (MK-0476) Metabolic Oxidation Products
    摘要:
    We report the chemical synthesis of six oxidized derivatives of MK-0476 (Montelukast, L-706631), which have been key tools in the identification of its metabolites. We have prepared three diastereoisomeric pairs of potential oxidative metabolites of MK-0476, starting from the (S)-hydroxy ester 7 in 10 and five steps, and starting from MK-0476 itself in one step. The key benzylic hydroxyl of 1 and 2 was introduced by a bromination and saponification reaction sequence. In the case of the hydroxyl of 3 and 4, the key step was the addition of a hydroxymethyl carbanion equivalent on ketone 20. The two sulfoxide 5 and 6 were prepared by a direct oxidation of MK-0476 with m-chloroperbenzoic acid.
    DOI:
    10.1021/jo9615817
  • 作为产物:
    参考文献:
    名称:
    Synthesis of Montelukast (MK-0476) Metabolic Oxidation Products
    摘要:
    We report the chemical synthesis of six oxidized derivatives of MK-0476 (Montelukast, L-706631), which have been key tools in the identification of its metabolites. We have prepared three diastereoisomeric pairs of potential oxidative metabolites of MK-0476, starting from the (S)-hydroxy ester 7 in 10 and five steps, and starting from MK-0476 itself in one step. The key benzylic hydroxyl of 1 and 2 was introduced by a bromination and saponification reaction sequence. In the case of the hydroxyl of 3 and 4, the key step was the addition of a hydroxymethyl carbanion equivalent on ketone 20. The two sulfoxide 5 and 6 were prepared by a direct oxidation of MK-0476 with m-chloroperbenzoic acid.
    DOI:
    10.1021/jo9615817
点击查看最新优质反应信息

文献信息

  • HETEROARYL DIOL ACIDS AS LEUKOTRIENE ANTAGONISTS
    申请人:MERCK FROSST CANADA INC.
    公开号:EP0840728A1
    公开(公告)日:1998-05-13
  • US5750539A
    申请人:——
    公开号:US5750539A
    公开(公告)日:1998-05-12
  • [EN] HETEROARYL DIOL ACIDS AS LEUKOTRIENE ANTAGONISTS<br/>[FR] ACIDES D'HETEROARYLE DIOL ANTAGONISTES DES LEUCOTRIENES
    申请人:MERCK FROSST CANADA INC.
    公开号:WO1996040638A1
    公开(公告)日:1996-12-19
    (EN) Compounds of formula (I) are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.(FR) L'invention se rapporte à des composés antagonistes des leucotriènes, qui sont représentés par la formule (I). Ces composés sont utiles comme agents anti-asmathiques, anti-allergiques, anti-inflammatoires et cytoprotecteurs. Ils sont également utiles dans le traitement de l'angine de poitrine, des spasmes cérébraux, de la glomérulonéphrite, de l'hépatite, de l'endotoxémie, de l'uvéité et du rejet d'allogreffes.
查看更多